Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients

Drugs
H D Langtry, R N Brogden

Abstract

Clarithromycin is a broad spectrum macrolide antibacterial agent active in vitro and effective in vivo against the major pathogens responsible for respiratory tract infections in immunocompetent patients. It is highly active in vitro against pathogens causing atypical pneumonia (Chlamydia pneumoniae, Mycoplasma pneumoniae and Legionella spp.) and has similar activity to other macrolides against Staphylococcus aureus. Streptococcus pyogenes, Moraxella catarrhalis and Streptococcus pneumoniae. Haemophilus influenzae is susceptible or intermediately susceptible to clarithromycin alone, but activity is enhanced when the parent drug and metabolite are combined in vitro. Absorption of clarithromycin is unaffected by food. More than half of an oral dose is systemically available as the parent drug and the active 14-hydroxy metabolite. Pharmacokinetics are nonlinear, with plasma concentrations increasing in more than proportion to the dosage. First-pass metabolism results in the rapid appearance of the active metabolite 14-hydroxy-clarithromycin in plasma. Clarithromycin and its active metabolite are found in greater concentrations in the tissues and fluids of the respiratory tract than in plasma. Dosage adjustments are required for pa...Continue Reading

Citations

Sep 13, 2000·Drugs & Aging·D Lieberman, D Lieberman
Jul 9, 2008·Drug Development and Industrial Pharmacy·Xiangrong ZhangDafang Zhong
May 1, 2010·Pharmaceutical Development and Technology·Bashar A AlkhalidiAlSayed Sallam
Sep 16, 2003·Biopharmaceutics & Drug Disposition·Ornrat LohitnavyPrawit Taytiwat
Nov 3, 1998·Clinical Pharmacology and Therapeutics·D OuelletJ M Leonard
Jun 11, 2003·Journal of Clinical Pharmacy and Therapeutics·M LohitnavyW Chaiyaput
May 6, 2009·Antimicrobial Agents and Chemotherapy·Khaled AbduljalilUwe Fuhr
Nov 28, 2007·Archives of Pharmacal Research·Qin LingHao, Leng Wei
Dec 21, 2007·Journal of Clinical Pharmacology·Vanitha J SekarRichard M W Hoetelmans
Mar 18, 2000·Antimicrobial Agents and Chemotherapy·D F BrophyR E Polk
Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S A Bernard, E Bruera
Aug 2, 2003·Drug Development and Industrial Pharmacy·M LohitnavyW Chaiyaput
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Malcolm J M Darkes, Caroline M Perry
Dec 11, 2019·Archives of Pharmacal Research·Choong-Min LeeSeok-Yong Lee
May 26, 2007·Clinical Drug Investigation·C H Nightingale
Aug 28, 2021·World Journal of Clinical Cases·Mei-Ying ZhangLi-Min Wang
Mar 12, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E RimbaraM Sasatsu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.